PIK3CA and neoplasm: In agreement, Lattanzio et al. observed a similar result in HNSCC cell lines [100] and Wang et al. also demonstrated reduced tumour burden in both PIK3CA- and RAS-expressing HNSCC xenografts, particularly in cetuximab resistant HNSCC cell lines [53].